The beef many here have is that the 3-4 clinical sites locations are what was originally promised almost 1 year ago before initial HREC application was made. Perhaps to save cost only 1 initial site was selected, but knowing the limited potential patient pool this was always going to be difficult. The communication with the market completely switched off after the last capital raise was done and I have only seen 1 media interview with Bob which was last month by 61 Financial aimed at Chinese investors.
Hopefully the BOD has seen that market is not happy with this delay, however as insiders still own very little of this, they are not as incentivise as other boards, if Bob wasn't buying last year when was in 1 to 2c range, doubt he would cough up to buy even now.
Look forward to additional clinical locations coming online and what plan they have for incentivising patients to participate in the trial.
IBX Price at posting:
9.5¢ Sentiment: Buy Disclosure: Held
